NCT06612086
Dapagliflozin in Mangement of Pulmonary Hypertension Patients
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
Notable Start date: Sep 21, 2024 to Oct 25, 2024v3 Show 5 more changesShow less
- Primary endpoint revised
- Study completion date: Oct 10, 2025 to Oct 10, 2026
- Secondary endpoint revised
- Publications: details revised at 5 of 7 entries
- Study title shortened, about 1 word
- Minor Secondary endpoints: details revised at 1 of 1 entry
- Study description revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Effect of Dapagliflozin on Right ventricle systolic function in patient with pulmonary Hypertension by speckle tract Echocardiography(RV Strain )
Timeframe: 6 month
Secondary (1)
Effect of Dapagliflozin on Quality of life for patient with pulmonary hypertension by Kansas City Cardiomyopathy Questionnaire Score
Arms and interventions
we follow up patient who take Dapagliflozin in patient with pulmonary hypertensionExperimental
we follow up patient who take Dapagliflozin in patient with pulmonary hypertension
Drugs: Dapagliflozin (Forxiga)
Sites
1 site in 1 country
- Assiut universityAsyut, Egypt